Results 81 to 90 of about 2,141 (187)

Abrocitinib for atopic dermatitis – Authors' reply [PDF]

The Lancet, 2021
Eric L, Simpson, Thomas, Bieber, Jacob P, Thyssen, Hernan, Valdez, Ricardo, Rojo   +4 more
openaire   +2 more sources

Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN

BACKGROUND: Treatment optimization may require dosing flexibility. The Phase 3 JADE REGIMEN trial (NCT03627767) evaluated maintenance of abrocitinib 200 mg-induced response in patients with moderate-to-severe atopic dermatitis (AD) randomly assigned to ...
Gubelin, W, Valdez, H, Blauvelt, A, Terry, K K, Simpson, E L, Biswas, P, Ruano, J, Güler, E, Silverberg, J I, Thyssen, J P, Weidinger, S, Feeney, C   +11 more
core   +1 more source

Abrocitinib

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Experience of abrocitinib in atopic dermatitis

Russian Journal of Skin and Venereal Diseases
Atopic dermatitis is an autoinflammatory, genetically determined, itchy disease characterized by a long, relapsing course and a sharp decrease in the patient’s quality of life. Atopic dermatitis is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and multi-environmental factors that affect the skin, causing intense ...
Nikolay G. Kochergin, Ali H. Abdulridha, Kristina A. Myzina   +2 more
openaire   +1 more source

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Journal of Dermatological Treatment
Background Dose-stratified real-world data for JAK1 inhibitors in AD are limited.Objective To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.Methods Multicenter, retrospective cohort study.
Abdullah Demirbaş, Mustafa Esen, Esin Diremsizoglu, Gözde Ulutaş Demirbaş   +3 more
doaj   +1 more source

Integrated efficacy and safety analysis of abrocitinib in adolescents with moderate‐to‐severe atopic dermatitis [PDF]

Background Abrocitinib has demonstrated long-term efficacy (48 weeks) and safety (~4 years) in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Koppensteiner, Herwig, Bangert, Christine, Biswas, Pinaki, Selfridge, Andrew, Wollenberg, Andreas, Flohr, Carsten, Alderfer, Justine, Irvine, Alan D., Fan, Haiyun, Paller, Amy S., Barbarot, Sébastien, Spergel, Jonathan M., Watkins, Melissa, Flohr, Carsten; id_orcid, Eichenfield, Lawrence F.   +14 more
core   +1 more source

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Dermatology and Therapy
Introduction Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities.
Eric L. Simpson, Jonathan I. Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M. Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner   +12 more
doaj   +1 more source

Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study

Pharmaceuticals
Background: Janus kinase (JAK) inhibitors have expanded the therapeutic landscape for moderate-to-severe atopic dermatitis (AD), yet real-world comparative data on upadacitinib and abrocitinib remain limited.
Ömer Karakoyun, Erhan Ayhan
doaj   +1 more source

Abrocitinib for Head and Neck Dermatitis: Case Series and Literature Review

Clinical, Cosmetic and Investigational Dermatology
Chuan Liu, Yu Pan, Jianxia Xiong, Aldi Dayu Saputra, Shuang Chen, Tao Cai Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence: Shuang Chen, Department of ...
Liu C, Pan Y, Xiong J, Saputra AD, Chen S, Cai T   +5 more
doaj  

Successful Treatment of Necrobiosis Lipoidica With Abrocitinib: A Case Report

Case Reports in Dermatology
Introduction: Necrobiosis lipoidica (NL) is a rare granulomatous disease with no standardized treatment guidelines. Case Presentation: We present a case of a patient who experienced ulcerative NL of the left leg for five years, during which traditional treatments proved ineffective.
Zhang, Yuping, Li, Yirong, Meng, Fengjiao, Li, Chen   +3 more
openaire   +2 more sources